toggle menu

Blog

News

NTAP/TPT Alternative Reimbursement Pathway Repealed for Breakthrough Devices – A Blow to Medical Device Innovation

By: Susan Lubejko PhD and Abigail Copeland PhD, Regulatory Affairs Specialists at Mittal Consulting On Tuesday August 4, the Centers for Medicare & Medicaid Services (CMS) finalized the repeal of the alternative pathway for FDA-designated Breakthrough Devices to access the new technology add-on payment (NTAP) and transitional pass-through (TPT) programs. Over the past five years, the […]

  • September 13, 2026
Uncategorized

Mittal Consulting Celebrates 5 Year Anniversary of Supporting MedTech Innovation

By- Mridul Mittal, Co-founder & COO, Mittal Consulting Celebrating 5 Incredible Years of Mittal Consulting! What started during the uncertain days of the global pandemic has grown into a powerful, purpose-driven force within the medical device industry. Today, as we proudly celebrate 5 incredible years of Mittal Consulting. We reflect on a journey defined by […]

  • September 9, 2025
News

What We’re Expecting to See at MedTech World Bay Area 2025

WHAT : Medtech World Bay Area Event WHERE : Signia Hotel by Hilton, San Jose                170 S Market St, San Jose, CA 95113 WHEN: June 27th, 2025 MedTech World Bay Area 2025 is just around the corner, and as the premiere regulatory affairs partner for startups in the medical device industry — and a […]

  • June 13, 2025
News

FDA New Draft Guidance to expand the use of Pre-determined Change control Plans (PCCPs) from just AI/ML to now all medical devices

By Elle Winn, Mittal Consulting On August 22, 2024, the FDA released a new draft guidance discussing Predetermined Change Control Plans for Medical Devices. Predetermined change control plans (PCCPs) are FDA-authorized plans to implement changes to a medical device at a later point that are included in and approved in a marketing submission to the […]

  • August 21, 2024
News

510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review

This draft guidance outlines FDA’s current thinking on key aspects of the 510(k) Third Party Review Program and third party review of Emergency Use Authorization (EUA) requests by describing FDA’s expectations for the reviews of 510(k) submissions and EUA requests by third party review organizations. This draft guidance provides updated recommendations on the 510(k) Third […]

  • December 12, 2023

Upcoming Events

Recent Posts

info@mittalconsulting.com

Drop us a line anytime!

Corporate Office

1327 SE Tacoma St., #133 Portland, Oregon 97202 USA

Mittal Consulting ©2025. All Rights Reserved.